Renal Cancer - Results from #2220

A lncRNA TCL6-miRNA-155 interaction regulates the Src-Akt-EMT network to mediate kidney cancer progression and metastasis. January 29, 2021

Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. January 29, 2021

Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-ana January 28, 2021

Radiomics to better characterize small renal masses. January 28, 2021

Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma. January 27, 2021

Potential diagnostic and prognostic value and regulatory relationship of long noncoding RNA CCAT1 and miR-130a-3p in clear cell renal cell carcinoma. January 27, 2021

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? January 27, 2021

Primary Small Cell Carcinoma of the Kidney: Disease Characteristics and Treatment Outcomes. January 26, 2021

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Diagnostic Imaging Product in the United States January 25, 2021

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. January 25, 2021

Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial. January 25, 2021

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. January 25, 2021

External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. January 25, 2021

Dana-Farber Research Supports FDA Approval for Combination of Nivolumab and Cabozantinib in Advanced Kidney Cancer January 23, 2021

Cabozantinib Receives U.S. FDA Approval as a First-Line Treatment in Combination with Nivolumab for Advanced Renal Cell Carcinoma January 22, 2021

The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. January 22, 2021

Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC). January 22, 2021

Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. January 22, 2021

Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. January 21, 2021

Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. January 21, 2021

Page 112 of 456